Global Xerosis Treatment Maeket Overview
Xerosis Treatment Maeket size was valued at USD 45.51 billion in 2024. The Xerosis Treatment Maeket industry is projected to grow from USD 48.03 billion in 2025 to USD 82.45 billion by 2035, exhibiting a compound annual growth rate (CAGR) of 7.71% during the forecast period (2025 - 2035). The growth of the global market is being driven by increased awareness, better diagnostic capabilities, and innovative product formulations.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Xerosis Treatment Maeket Trend
Rising awareness and improved diagnosis
Rising awareness and improved diagnosis are playing a crucial role in accelerating the growth of the Xerosis Treatment Maeket. Over the past few years, there has been a significant increase in public awareness about xerosis, a chronic skin condition characterized by dry, rough, and flaky skin. This surge in awareness has been fueled by a variety of factors, including widespread educational campaigns, the growing influence of digital media, and active involvement from healthcare professionals.
As a result, more individuals are recognizing the symptoms of xerosis and seeking medical consultation for timely treatment. Enhanced access to information has also empowered patients to understand the importance of early diagnosis, which has led to the increased utilization of specialized treatments. The earlier the condition is identified, the more effective and efficient the treatment is, leading to higher demand for both over-the-counter and prescription-based solutions.
Moreover, the Xerosis Treatment Maeket is witnessing a surge in product launches as companies strive to meet the growing demand for effective solutions for dry skin conditions. With the increasing prevalence of xerosis and heightened awareness among both consumers and healthcare providers, pharmaceutical and skincare companies are introducing a wide range of innovative products, from topical emollients and moisturizers to advanced prescription therapies. These new product offerings are designed to address the diverse needs of xerosis patients, with formulations that provide enhanced hydration, improve skin barrier function, and offer long-lasting relief.
In conclusion, the Xerosis Treatment Maeket is rapidly growing due to increased awareness and improved diagnosis of the condition. This has led to greater recognition of symptoms and earlier treatment, boosting demand for both over the counter and prescription solutions. The surge in product innovation reflects the market's response to the rising need for effective dry skin treatments. As awareness continues to grow, both consumers and healthcare providers will drive further advancements in treatment options.
Xerosis Treatment Maeket Segment Insights
Xerosis Treatment Maeket Type Insights
Based on type, the Xerosis Treatment Maeket has been bifurcated into medication and personal care products. Medication is further segmented into antihistamines, corticosteroids, calcineurin inhibitors, anti-inflammatory, immunomodulators, and others. The personal care products segment held the largest market share in 2024, and the medication segment is the fastest-growing segment during the forecast period (2025 -2035). Within the Medication category, there are several key subsegments, each catering to different aspects of xerosis (dry skin) treatment, depending on the severity and underlying causes of the condition.
Antihistamines are usually prescribed in situations where xerosis is associated with allergic reaction or itching. These drugs will work by inhibiting histamine, which is a substance released in an allergic reaction, thereby decreasing the itching and irritation commonly present with dry skin conditions. Oral antihistamines such as diphenhydramine or cetirizine can be prescribed for the treatment of symptoms while topical antihistamines can be used for localized reactions on the skin.
FIGURE 2: Xerosis Treatment Maeket, BY TYPE, 2024 & 2035 (USD BILLION)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Xerosis Treatment Maeket Form Insights
Based on form, the Xerosis Treatment Maeket has been segmented into tablets, lotion, cream, ointment, gels, shower foams, and others. The cream segment held the largest market in 2024, and the shower foams segment is the fastest growing segment during the forecast period.
The tablets segment in the Xerosis Treatment Maeket is driven by a growing prevalence of chronic conditions like diabetes, hypothyroidism, and other systemic disorders leading to severe dryness of the skin. Patients with such underlying health issues often require oral medications to treat the cause of xerosis, and hence, tablet-based treatments gain importance. Advances in systemic therapies specially targeted towards skin hydration and repair are further fueling tablet adoption in the segment.
Xerosis Treatment Maeket Age Group Insights
Based on age group, the Xerosis Treatment Maeket has been segmented into paediatrics, adults, and elderly. The adults segment held the largest market in 2024, and the elderly segment is the fastest growing segment during the forecast period.
The paediatrics segment in the Xerosis Treatment Maeket is mainly contributed by the increasing incidence of skin dryness and conditions such as eczema among children, largely attributed to genetic predisposition, environmental factors, and allergies. Parents increasingly want gentle, hypoallergenic products specifically designed for kids' sensitive skin. So, manufacturers have also promoted pediatric-friendly formulations devoid of harsh chemicals, fragrances, and dyes. Also, the rising consciousness of maintaining healthy skin from childhood and thereby preventing future complications is fueling the growth of segments.
Xerosis Treatment Maeket Gender Insights
The female segment held the largest market in 2024, and the male segment is the fastest growing segment during the forecast period.
The male segment in the Xerosis Treatment Maeket is driven by the growing awareness among men about skin health and the importance of hydration in maintaining a healthy skin barrier. Men are becoming more proactive in addressing skin concerns, including xerosis, as societal norms around male grooming continue to evolve.
The market has responded with gender-specific products, like light and non-greasy formulations, that can easily absorb into the skin quickly, according to men's preference. Long exposure to sunlight and occupational exposure are other environmental factors, which have a greater demand for targeted xerosis treatments among males. Campaigns by skincare brands for male grooming propel this growth segment.
Xerosis Treatment Maeket Distribution Channel Insights
Based on distribution channel, the Xerosis Treatment Maeket has been bifurcated into online and offline. The offline segment held the largest market in 2024, and the online segment is the fastest growing segment during the forecast period.
The online distribution channels segment of the Xerosis Treatment Maeket has experienced remarkable growth as consumers increasingly prefer online shopping platforms that provide convenience, accessibility, and a broad range of products. The e-commerce websites and online pharmacies have emerged as the prime B2C channels through which consumers can browse, compare, and purchase xerosis treatment products from the comfort of their homes. These platforms often provide detailed product descriptions, customer reviews, and discounts, which enhance the shopping experience and encourage adoption.
Xerosis Treatment Maeket Regional Insights
By region, the market is divided into North America, Europe, Asia-Pacific, and the Rest of the World. The North American xerosis treatment market, covering Canada and Mexico, is seeing steady growth, driven by the rising demand for non-invasive treatments. Market growth in the region is mainly contributed by the increased incidence of xerosis and other similar conditions like eczema and psoriasis in both the US and Canada.
For Instance, according to the National Psoriasis Foundation (US), More than 8 million people in the US are affected by psoriasis. This increased incidence of skin-related disorders has heightened the demand for effective treatments for dry skin, thereby boosting the market for xerosis treatment products in the region. The growing awareness about skincare, coupled with a significant shift towards self-care and natural remedies, further contributes to the surge in demand for both over the counter and prescription treatments. The availability of various treatment options, including lotions, creams, and medicated ointments, allows consumers to address symptoms of xerosis based on their needs, driving market expansion.
Further, the major countries studied are: The US, Canada, Brazil, Germany, France, the UK, Italy, Spain, China, India, Japan, South Korea, and Australia.
FIGURE 3: Xerosis Treatment Maeket, BY REGION, 2024 & 2035 (USD BILLION)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The growth of the xerosis treatment market in Europe is driven by the increasing prevalence of skin conditions such as xerosis, eczema, and psoriasis, especially in older populations. The European market is witnessing a rise in demand for both topical and oral treatments, fueled by growing awareness of skin health and the availability of a variety of treatment options. In particular, the, Germany, France, and UK account for a significant share of the market due to their advanced healthcare systems and widespread access to dermatological treatments. According to the European Academy of Dermatology and Venereology (EADV), at least 50% of people over the age of 65 suffer from xerosis, further fueling the demand for effective skincare solutions.
In the Asia-Pacific (APAC) region, the market for xerosis treatment is growing due to increases in skin disorders, mainly in Japan, China, and India. Increased pollution levels, changing climate patterns, and urbanization contribute to a growing case of xerosis and related skin problems. In addition, the increasing concern about health and skincare is boosting the demand for medical and personal care products. The WHO reports that skin disorders and dry conditions are highly common in various APAC countries; therefore, the region is a significant target market for xerosis treatment solutions. Moreover, China xerosis treatment market held the largest market share in 2024, and Australia xerosis treatment market is the fastest growing market in the Asia-Pacific region.
Xerosis Treatment Maeket Key Market Players & Competitive Insights
The Xerosis Treatment Maeket is distinguished by the presence of numerous regional and local players catering to the Xerosis Treatment Maeket. The market is distinguished by the existence of both prescription-based medicines and over the counter (OTC) drugs, which cater to a variety of customer needs. Larger companies use their established brand reputation, global distribution networks, and research capacity to maintain dominance,
whereas smaller, specialized enterprises concentrate on producing limited, focused solutions with a particular emphasis on natural and organic ingredients. Competition has increased in response to rising demand for effective treatments, which is being driven by challenges such as aging populations and environmental influences on skin health.
Amgen Inc. (Amgen) is a biotechnology firm that develops, creates, manufactures, and sells modern human therapeutics to treat people with life-threatening diseases. The company discovers, develops, manufactures and delivers innovative medicines aimed at combating some of the world’s most challenging diseases. They focus on areas with high unmet medical needs and leverage their expertise to create solutions that significantly improve patient outcomes and lessen the social and economic impact of illness.
The company manufactures both biologics and small molecule drugs. Moreover, in August 2024, Amgen announced that Otezla (apremilast) is now available for pediatric use in the U.S. Earlier this year, the U.S. Food and Drug Administration (FDA) approved Otezla for treating moderate to severe plaque psoriasis in children and adolescents aged 6 and older, weighing at least 20 kg (44 lb), and who are candidates for phototherapy or systemic therapy.
Key Companies in the Xerosis Treatment Market include
- Bayer AG (Germany)
- Reddy’s Laboratories Ltd. (India)
- Johnson & Johnson Inc. (US)
- Galderma (Switzerland)
- Thornton & Ross Ltd. (UK)
- Amgen Inc. (US)
- Procter & Gamble (US)
- Unilever (UK)
- Pfizer Inc. (US)
- Cipla (India)
Pharmaceutical Excipients Industry Developments
August 2024: Amgen Inc. announced that Otezla (apremilast) is now available for pediatric use in the U.S. Earlier this year, the U.S. Food and Drug Administration (FDA) approved Otezla for treating moderate to severe plaque psoriasis in children and adolescents aged 6 and older, weighing at least 20 kg (44 lb), and who are candidates for phototherapy or systemic therapy.
January 2023: Olay has introduced the Niacinamide+Peptide 24 Face Moisturiser, a product packed with powerful niacinamide and amino acid peptides. Formulated with some of the most popular skincare ingredients of 2023, this moisturiser is the result of extensive research designed to meet consumer needs.
XEROSIS TREATMENT MARKET Segmentation
Xerosis Treatment Maeket Type Outlook
- Medication
- Antihistamines
- Corticosteroids
- Calcineurin Inhibitors
- Anti-Inflammatory
- Immunomodulators
- Other
- Personal Care Products
Xerosis Treatment Maeket Form Outlook
- Tablets
- Lotion
- Cream
- Cream
- Ointment
- Shower Forms
- Others
Xerosis Treatment Maeket Age Group Outlook
- Paediatrics
- Adults
- Elderly
Xerosis Treatment Maeket Gender Outlook
Xerosis Treatment Maeket Distribution Channel Outlook
Xerosis Treatment Maeket Regional Outlook
-
North America
- US
- Canada
- Mexico
-
Europe
- Germany
- France
- UK
- Italy
- Spain
- Itay
- Russia
- Rest of Europe
-
Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia
- Malaysia
- Thailand
- Indonesia
- Rest of Asia-Pacific
-
South America
- Brazil
- Mexico
- Argentina
- Rest of South America
-
Middle East and Africa
- Brazil
- Mexico
- Argentina
- Rest of South America
| Report Attribute/Metric |
Details |
| Market Size 2024 |
USD 45.51 billion |
| Market Size 2025 |
USD 48.03 billion |
| Market Size 2035 |
USD 82.45 billion |
| Compound Annual Growth Rate (CAGR) |
7.71% (2025-2035) |
| Base Year |
2024 |
| Forecast Period |
2025-2035 |
| Historical Data |
2019 to 2023 |
| Forecast Units |
Value (USD Billion) |
| Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Type, Form, Age Group, Gender, Distribution Channel, and Region |
| Geographies Covered |
North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered |
The US, Canada, Brazil, Germany, France, the UK, Italy, Spain, China, India, Japan, South Korea, Australia. |
| Key Companies Profiled |
Bayer AG (Germany), Dr.Reddy’s Laboratories Ltd. (India), Johnson & Johnson Inc. (US), Galderma (Switzerland), Thornton & Ross Ltd. (UK), Amgen Inc. (US), Procter & Gamble (US), Unilever (UK), Pfizer Inc. (US), and Cipla (India) |
| Key Market Opportunities |
·       Growing geriatric population ·       Increase in self-care practices for xerosis |
| Key Market Drivers |
·       Growing geriatric population ·       Increase in self-care practices for xerosis |
Frequently Asked Questions (FAQ) :
The XEROSIS TREATMENT MARKET is anticipated to reach 82.45 billion by 2035 at a CAGR of 7.71% during the forecast period of 2025-2035.
The US held 88.15% share of North America for the XEROSIS TREATMENT MARKET in 2024.
The XEROSIS TREATMENT MARKET is expected to grow at a 7.71% CAGR during the forecast period from 2025 to 2035.
The North America regional market held the largest market share in the XEROSIS TREATMENT MARKET.
The key players include Bayer AG (Germany), Dr.Reddy’s Laboratories Ltd. (India), Johnson & Johnson Inc. (US), Galderma (Switzerland), Thornton & Ross Ltd. (UK), Amgen Inc. (US), Procter & Gamble (US), Unilever (UK), Pfizer Inc. (US), and Cipla (India).
The personal care products of type segment led the XEROSIS TREATMENT MARKET in 2024.
